Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2021-04-28
Target enrollment:
Participant gender:
Summary
Based upon biological behavior, those mCRC patients who respond well (SD, PR or CR according
to RECIST Criteria) after 16-18 weeks of standard doublet chemotherapy as induction may
enrolled into this study, randomly divided into capecitabine metronomic group or standard
dosage group. The duration of disease control after randomization(PFS2) and progression free
survival from enrollment (PFS1) are primary endpoints. Meanwhile, the overall survival,
safety and quality of life are secondary endpoints. Exploratory markers involving
angiogenesis (serum VEGF, PDGF, Tie-1 and Tie2, etc) and immune function (CD clusters, serum
tumor mutation burden(TMB), etc), are conducted via liquid biopsy.